Page 87 - Read Online

Page 20 of 22 Guerriero et al. Hepatoma Res 2019;5:6 I http://dx.doi.org/10.20517/2394-5079.2018.108

(HCC): clinical analyses of patients and an HCC rat model. Int J Clin Exp Pathol 2015;8:1466-78.
80. Lee YR, Kim G, Tak WY, Jang SY, Kweon YO, et al. Circulating exosomal non-coding RNAs as prognostic biomarkers in human
hepatocellular carcinoma. Int J Cancer 201810.1002/ijc.31931.
81. Liver EAftSot. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182-236.
82. Ng KT, Lo CM, Wong N, Li CX, Qi X, et al. Early-phase circulating miRNAs predict tumor recurrence and survival of hepatocellular
carcinoma patients after liver transplantation. Oncotarget 2016;7:19824-39.
83. European Association for Study of L, European Organisation for R, Treatment of C. EASL-EORTC clinical practice guidelines:
management of hepatocellular carcinoma. Eur J Cancer 2012;48:599-641.
84. Kim SS, Nam JS, Cho HJ, Won JH, Kim JW, et al. Plasma micoRNA-122 as a predictive marker for treatment response following
transarterial chemoembolization in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2017;32:199-207.
85. Suehiro T, Miyaaki H, Kanda Y, Shibata H, Honda T, et al. Serum exosomal microRNA-122 and microRNA-21 as predictive
biomarkers in transarterial chemoembolization-treated hepatocellular carcinoma patients. Oncol Lett 2018;16:3267-73.
86. Cui L, Hu Y, Bai B, Zhang S. Serum miR-335 Level is Associated with the Treatment Response to Trans-Arterial Chemoembolization
and Prognosis in Patients with Hepatocellular Carcinoma. Cell Physiol Biochem 2015;37:276-83.
87. Liu M, Liu J, Wang L, Wu H, Zhou C, et al. Association of serum microRNA expression in hepatocellular carcinomas treated with
transarterial chemoembolization and patient survival. PLoS One 2014;9:e109347.
88. Fornari F, Pollutri D, Patrizi C, La Bella T, Marinelli S, et al. In hepatocellular carcinoma miR-221 modulates Sorafenib resistance
through inhibition of caspase-3 mediated apoptosis. Clin Cancer Res 201710.1158/1078-0432.CCR-16-1464.
89. Nishida N, Arizumi T, Hagiwara S, Ida H, Sakurai T, et al. MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in
Human Hepatocellular Carcinoma. Liver Cancer 2017;6:113-25.
90. Geisler S, Coller J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol
2013;14:699-712.
91. Ransohoff JD, Wei Y, Khavari PA. The functions and unique features of long intergenic non-coding RNA. Nat Rev Mol Cell Biol
2018;19:143-57.
92. Hauptman N, Glavac D. Long non-coding RNA in cancer. Int J Mol Sci 2013;14:4655-69.
93. Tang Y, Cheung BB, Atmadibrata B, Marshall GM, Dinger ME, et al. The regulatory role of long noncoding RNAs in cancer. Cancer
Lett 2017;391:12-9.
94. DiStefano JK. Long noncoding RNAs in the initiation, progression, and metastasis of hepatocellular carcinoma. Noncoding RNA Res
2017;2:129-36.
95. Lu J, Xie F, Geng L, Shen W, Sui C, et al. Investigation of serum lncRNA-uc003wbd and lncRNA-AF085935 expression profile in
patients with hepatocellular carcinoma and HBV. Tumour Biol 2015;36:3231-6.
96. Xu H, Chen Y, Dong X, Wang X. Serum Exosomal Long Noncoding RNAs ENSG00000258332.1 and LINC00635 for the Diagnosis
and Prognosis of Hepatocellular Carcinoma. Cancer Epidemiol Biomarkers Prev 2018;27:710-6.
97. Gao S, Xu X, Wang Y, Zhang W, Wang X. Diagnostic utility of plasma lncRNA small nucleolar RNA host gene 1 in patients with
hepatocellular carcinoma. Mol Med Rep 2018;18:3305-13.
98. Luo P, Liang C, Zhang X, Liu X, Wang Y, et al. Identification of long non-coding RNA ZFAS1 as a novel biomarker for diagnosis of
HCC. Biosci Rep 2018;38.
99. Kamel MM, Matboli M, Sallam M, Montasser IF, Saad AS, et al. Investigation of long noncoding RNAs expression profile as potential
serum biomarkers in patients with hepatocellular carcinoma. Transl Res 2016;168:134-45.
100. Yu J, Han J, Zhang J, Li G, Liu H, et al. The long noncoding RNAs PVT1 and uc002mbe.2 in sera provide a new supplementary
method for hepatocellular carcinoma diagnosis. Medicine (Baltimore) 2016;95:e4436.
101. Ma W, Wang H, Jing W, Zhou F, Chang L, et al. Downregulation of long non-coding RNAs JPX and XIST is associated with the
prognosis of hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2017;41:163-70.
102. Wang ZF, Hu R, Pang JM, Zhang GZ, Yan W, et al. Serum long noncoding RNA LRB1 as a potential biomarker for predicting the
diagnosis and prognosis of human hepatocellular carcinoma. Oncol Lett 2018;16:1593-601.
103. Zheng ZK, Pang C, Yang Y, Duan Q, Zhang J, et al. Serum long noncoding RNA urothelial carcinoma-associated 1: A novel biomarker
for diagnosis and prognosis of hepatocellular carcinoma. J Int Med Res 2018;46:348-56.
104. Li J, Wang X, Tang J, Jiang R, Zhang W, et al. HULC and Linc00152 Act as Novel Biomarkers in Predicting Diagnosis of
Hepatocellular Carcinoma. Cell Physiol Biochem 2015;37:687-96.
105. Ma X, Wang X, Yang C, Wang Z, Han B, et al. DANCR Acts as a Diagnostic Biomarker and Promotes Tumor Growth and Metastasis
in Hepatocellular Carcinoma. Anticancer Res 2016;36:6389-98.
106. Li J, Gao J, Kan A, Hao T, Huang L. SNHG and UCA1 as prognostic molecular biomarkers in hepatocellular carcinoma: recent
research and meta-analysis. Minerva Med 2017;108:568-74.
107. Xie Z, Zhou F, Yang Y, Li L, Lei Y, et al. Lnc-PCDH9-13:1 Is a Hypersensitive and Specific Biomarker for Early Hepatocellular
Carcinoma. EBioMedicine 2018;33:57-67.
108. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable
hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73.
109. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, et al. Cabozantinib in Patients with Advanced and Progressing
Hepatocellular Carcinoma. N Engl J Med 2018;379:54-63.
110. Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, et al. High-throughput droplet digital PCR system for absolute
quantitation of DNA copy number. Anal Chem 2011;83:8604-10.
111. Ferracin M, Lupini L, Salamon I, Saccenti E, Zanzi MV, et al. Absolute quantification of cell-free microRNAs in cancer patients.
Oncotarget 2015;6:14545-55.
112. Witwer KW. Circulating microRNA biomarker studies: pitfalls and potential solutions. Clin Chem 2015;61:56-63.